we are also in the final planning stages for a phase 2/3 trial for lenzilumab to treat patients who have undergone allogeneic hematopoietic stem cell therapy ( “ hsct ” ) who are at high and intermediate risk for acute gvhd . the trial is expected to be conducted by the impact partnership , a collection of 22 stem cell transplant centers located in the united kingdom . 92 our proprietary , patented humaneered technology platform is a method for converting existing antibodies ( typically murine ) into engineered , high-affinity human antibodies designed for therapeutic use , particularly with acute and chronic conditions . we have developed or in-licensed targets or research antibodies , typically from academic institutions , and then applied our humaneered technology to produce them . lenzilumab and our other two product candidates , ifabotuzumab and hgen005 , are humaneered monoclonal antibodies . our humaneered antibodies are closer to human antibodies than chimeric or conventionally humanized antibodies and have a high affinity for their target but low immunogenicity . we believe our humaneered antibodies offer additional advantages , such as high potency , a slow off-rate and a lower likelihood to induce an inappropriate immune response or infusion related reactions . our pipeline our lenzilumab-based clinical-stage pipeline comprises a phase 3 potential registration study in covid-19 which has fully enrolled , the nih-sponsored and funded activ-5/bet program in covid-19 , a currently enrolling phase 1b/2 study ( zuma-19 ) as sequenced therapy of lenzilumab and yescarta , a planned phase 2/3 study in acute gvhd , and a planned phase 2 study in cmml , the latter two of which we expect will be majority funded by partners . while the majority of our clinical programs involve lenzilumab , we have also fully enrolled an ifabotuzumab phase 1 study in gbm . except for the potential of lenzilumab for covid-19 under an eua , our product candidates are in the clinical stage of development and will require substantial time , resources , research and development , and regulatory approval prior to commercialization . furthermore , it may be years before any of our products are approved for use , if at all . our current pipeline is depicted below : 1 phase 3 may not be necessary for approval in zuma-19 ; precedent is car-ts to date have been approved on phase 2 data 2 uk 3 us , eu , australia results of operations general at december 31 , 2020 , we had an accumulated deficit of $ 374.4 million , primarily as a result of research and development and general and administrative expenses as well as costs incurred in reorganization . while we may in the future generate revenue from a variety of sources , including license fees , milestone payments , and research and development payments in connection with strategic partnerships , our product candidates are at an early stage of development and may never be successfully developed or commercialized . accordingly , we expect to continue to incur substantial losses from operations for the foreseeable future , and there can be no assurance that we will ever generate significant revenue or profits . 93 research and development expenses conducting research and development is central to our business model . we expense both internal and external research and development costs as incurred . we track external research and development costs incurred by project for each of our clinical programs . our external research and development costs consist primarily of : · expenses incurred under agreements with contract research organizations , investigative sites , and consultants that conduct our clinical trials and a substantial portion of our pre-clinical activities ; · the cost of acquiring and manufacturing clinical trial and eua materials prior to receiving an eua ; and · other costs associated with development activities , including additional studies . other research and development costs consist primarily of internal research and development costs such as salaries and related fringe benefit costs for our employees ( such as workers compensation and health insurance premiums ) , stock-based compensation charges , and external costs not allocated to one of our clinical programs . internal research and development costs generally benefit multiple projects and are not separately tracked per project . the following table shows our total research and development expenses for the years ended december 31 , 2020 and 2019 : replace_table_token_1_th selling , general and administrative expenses selling , general and administrative expenses consist principally of personnel-related costs , costs related to our preparation for commercialization of lenzilumab , professional fees for legal and patent expenses , consulting , audit and tax services , investor and public relations costs , rent and other general operating expenses not otherwise included in research and development . for the years ended december 31 , 2020 and 2019 , selling , general and administrative expenses were $ 15.8 million and $ 6.3 million , respectively . 94 comparison of years ended december 31 , 2020 and 2019 ( $ 000 's ) replace_table_token_2_th license revenue increased $ 0.3 million in 2020 from $ 0 for the year ended december 31 , 2019 to $ 0.3 million for the year ended december 31 , 2020. the increase is due to the signing of the south korea agreement , described in more detail in note 3 to the consolidated financial statements included in this annual report on form 10-k. research and development expenses increased $ 70.1 million in 2020 from $ 2.6 million for the year ended december 31 , 2019 to $ 72.7 million for the year ended december 31 , 2020. the increase is primarily due to increased clinical trial and clinical material manufacturing costs related to the covid-19 clinical trials . story_separator_special_tag of these , we issued 316,666 shares to cheval . dr. dale chappell , who was serving as our ex-officio chief scientific officer at the time and currently serves as our chief scientific officer , controls bhc and reports beneficial ownership of all shares held by it and its affiliates , including cheval . after giving effect to the shares issued upon such conversions , no convertible notes issued in 2018 or 2019 were outstanding as of december 31 , 2020. as of december 31 , 2019 , we had accrued $ 0.1 million in interest related to the 2019 notes . interest expense related to the 2019 notes , recorded during the year ended december 31 , 2020 , was approximately $ 219,000 . 100 2019 bridge notes on june 28 , 2019 , we issued three short-term , secured bridge notes ( the “ june bridge notes ” ) evidencing an aggregate of $ 1.7 million of loans made to us by three parties : cheval , an affiliate of bhc , our controlling stockholder at the time , lent $ 750,000 ; nomis bay , our second largest stockholder at the time , lent $ 750,000 ; and dr. durrant , our chief executive officer and chairman of our board of directors , lent $ 200,000. the $ 1.7 million in proceeds was recorded as advance notes in the consolidated balance sheet as of december 31 , 2019. as previously disclosed , the june bridge notes were repaid in june 2020 with proceeds from the private placement , and the june bridge notes were extinguished . on november 12 , 2019 , we issued two short-term , secured bridge notes ( the “ november bridge notes ” and together with the june bridge notes , the “ 2019 bridge notes ” ) evidencing an aggregate of $ 350,000 of loans made us by two parties : cheval , an affiliate of bhc , our controlling stockholder at the time , lent $ 250,000 ; and cameron durrant , m.d . , mba , our chief executive officer and chairman of our board of directors , lent $ 100,000 . as previously disclosed , the november bridge notes were repaid in june 2020 with proceeds from the private placement . in april 2020 , we issued two short-term , secured bridge notes ( the “ april bridge notes ” and together with the june bridge notes and the november bridge notes , the “ bridge notes ” ) evidencing an aggregate of $ 350,000 of loans made to us : cheval , an affiliate of bhc , our controlling stockholder at the time , loaned $ 100,000 , and nomis bay , our second largest stockholder , loaned $ 250,000. the proceeds from the april bridge notes were used for working capital and general corporate purposes . as previously disclosed , these april bridge notes were repaid in june 2020 with proceeds from the private placement , and these bridge notes were extinguished . the bridge notes were secured by a lien on substantially all the company 's assets , which liens have been released . the bridge notes accrued interest at a rate of 7.0 % per annum . interest expense related to the bridge notes , recorded during the year ended december 31 , 2020 , was approximately $ 66,000 . 2020 convertible redeemable notes in march 2020 , we delivered two convertible redeemable promissory notes ( the “ 2020 notes ” ) evidencing loans with an aggregate principal amount of $ 518,333 made to us . the 2020 notes accrued interest at a rate of 7.0 % per annum and contained an original issue discount of $ 33,000 and $ 18,833 , respectively . we used the proceeds from the 2020 notes for working capital . as previously disclosed , the notes were repaid in june 2020 with proceeds from the private placement , and the notes were extinguished . interest expense related to the 2020 notes , recorded during the year ended december 31 , 2020 , was approximately $ 165,000. interest expense includes the original issue discount amortization of approximately $ 52,000 for the year ended december 31 , 2020. equity line of credit on november 8 , 2019 , we entered into a purchase agreement and a registration rights agreement with lincoln park , pursuant to which we had the right to sell to lincoln park up to $ 20,000,000 in shares of our common stock , subject to certain limitations and conditions set forth in the purchase agreement . in connection with the signing of the eloc purchase agreement on november 8 , 2019 , we issued 141,318 shares of its common stock to lpc . the issuance of the shares was recorded as debt issuance costs in common stock and additional paid-in capital with no net effect on stockholders ' equity ( deficit ) . during the months of december 2019 and january 2020 , we issued a total of 140,000 shares for aggregate proceeds of $ 0.3 million under the eloc purchase agreement . on june 2 , 2020 , following completion of the private placement , we notified lpc of our decision to terminate the eloc purchase agreement . the termination of the eloc purchase agreement became effective on june 3 , 2020 . 101 contracts eversana agreement on january 10 , 2021 , we announced that we had entered into a master services agreement ( the “ eversana agreement ” ) with eveersana life science services , llc ( “ eversana ” ) pursuant to which eversana will serve as our end-to-end commercial partner , providing us with a full suite of services in connection with the potential launch of lenzilumab . we will pay eversana fees and reimburse it for its expenses in performing the services as established in applicable statements of work . eversana has agreed to defer its fees pending our receipt of an

liquidity and capital resources since our inception , we have financed our operations primarily through proceeds from the public offerings and private placements of our common and preferred stock , debt financings , interest income earned on cash , and cash equivalents , and marketable securities , borrowings against lines of credit , and receipts from prior collaboration agreements . at december 31 , 2020 , we had cash and cash equivalents of $ 67.7 million . as of march 5,2021 , we had cash and cash equivalents of $ 74.3 million . primary sources of and uses of cash the following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below ( $ 000 's ) : replace_table_token_3_th net cash used in operating activities was $ 69.9 million and $ 4.0 million for the years ended december 31 , 2020 and 2019 , respectively . cash used in operating activities in 2019 primarily related to our net loss of $ 10.3 million , adjusted for non-cash items , such as $ 2.0 million in stock-based compensation , changes in operating assets and liabilities of $ 4.1 million and other non-cash items of $ 0.2 million . cash used in operating activities in 2020 primarily related to our net loss of $ 89.0 million , adjusted for non-cash items , such as $ 2.1 million in stock-based compensation , changes in operating assets and liabilities of $ 16.6 million and other non-cash items of $ 0.4 million . net cash used in investing activities was $ 20,000 for the year ended december 31 , 2020. this relates to the acquisition of intangible assets .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources since our inception , we have financed our operations primarily through proceeds from the public offerings and private placements of our common and preferred stock , debt financings , interest income earned on cash , and cash equivalents , and marketable securities , borrowings against lines of credit , and receipts from prior collaboration agreements . at december 31 , 2020 , we had cash and cash equivalents of $ 67.7 million . as of march 5,2021 , we had cash and cash equivalents of $ 74.3 million . primary sources of and uses of cash the following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below ( $ 000 's ) : replace_table_token_3_th net cash used in operating activities was $ 69.9 million and $ 4.0 million for the years ended december 31 , 2020 and 2019 , respectively . cash used in operating activities in 2019 primarily related to our net loss of $ 10.3 million , adjusted for non-cash items , such as $ 2.0 million in stock-based compensation , changes in operating assets and liabilities of $ 4.1 million and other non-cash items of $ 0.2 million . cash used in operating activities in 2020 primarily related to our net loss of $ 89.0 million , adjusted for non-cash items , such as $ 2.1 million in stock-based compensation , changes in operating assets and liabilities of $ 16.6 million and other non-cash items of $ 0.4 million . net cash used in investing activities was $ 20,000 for the year ended december 31 , 2020. this relates to the acquisition of intangible assets .
```    
 Suspicious Activity Report : we are also in the final planning stages for a phase 2/3 trial for lenzilumab to treat patients who have undergone allogeneic hematopoietic stem cell therapy ( “ hsct ” ) who are at high and intermediate risk for acute gvhd . the trial is expected to be conducted by the impact partnership , a collection of 22 stem cell transplant centers located in the united kingdom . 92 our proprietary , patented humaneered technology platform is a method for converting existing antibodies ( typically murine ) into engineered , high-affinity human antibodies designed for therapeutic use , particularly with acute and chronic conditions . we have developed or in-licensed targets or research antibodies , typically from academic institutions , and then applied our humaneered technology to produce them . lenzilumab and our other two product candidates , ifabotuzumab and hgen005 , are humaneered monoclonal antibodies . our humaneered antibodies are closer to human antibodies than chimeric or conventionally humanized antibodies and have a high affinity for their target but low immunogenicity . we believe our humaneered antibodies offer additional advantages , such as high potency , a slow off-rate and a lower likelihood to induce an inappropriate immune response or infusion related reactions . our pipeline our lenzilumab-based clinical-stage pipeline comprises a phase 3 potential registration study in covid-19 which has fully enrolled , the nih-sponsored and funded activ-5/bet program in covid-19 , a currently enrolling phase 1b/2 study ( zuma-19 ) as sequenced therapy of lenzilumab and yescarta , a planned phase 2/3 study in acute gvhd , and a planned phase 2 study in cmml , the latter two of which we expect will be majority funded by partners . while the majority of our clinical programs involve lenzilumab , we have also fully enrolled an ifabotuzumab phase 1 study in gbm . except for the potential of lenzilumab for covid-19 under an eua , our product candidates are in the clinical stage of development and will require substantial time , resources , research and development , and regulatory approval prior to commercialization . furthermore , it may be years before any of our products are approved for use , if at all . our current pipeline is depicted below : 1 phase 3 may not be necessary for approval in zuma-19 ; precedent is car-ts to date have been approved on phase 2 data 2 uk 3 us , eu , australia results of operations general at december 31 , 2020 , we had an accumulated deficit of $ 374.4 million , primarily as a result of research and development and general and administrative expenses as well as costs incurred in reorganization . while we may in the future generate revenue from a variety of sources , including license fees , milestone payments , and research and development payments in connection with strategic partnerships , our product candidates are at an early stage of development and may never be successfully developed or commercialized . accordingly , we expect to continue to incur substantial losses from operations for the foreseeable future , and there can be no assurance that we will ever generate significant revenue or profits . 93 research and development expenses conducting research and development is central to our business model . we expense both internal and external research and development costs as incurred . we track external research and development costs incurred by project for each of our clinical programs . our external research and development costs consist primarily of : · expenses incurred under agreements with contract research organizations , investigative sites , and consultants that conduct our clinical trials and a substantial portion of our pre-clinical activities ; · the cost of acquiring and manufacturing clinical trial and eua materials prior to receiving an eua ; and · other costs associated with development activities , including additional studies . other research and development costs consist primarily of internal research and development costs such as salaries and related fringe benefit costs for our employees ( such as workers compensation and health insurance premiums ) , stock-based compensation charges , and external costs not allocated to one of our clinical programs . internal research and development costs generally benefit multiple projects and are not separately tracked per project . the following table shows our total research and development expenses for the years ended december 31 , 2020 and 2019 : replace_table_token_1_th selling , general and administrative expenses selling , general and administrative expenses consist principally of personnel-related costs , costs related to our preparation for commercialization of lenzilumab , professional fees for legal and patent expenses , consulting , audit and tax services , investor and public relations costs , rent and other general operating expenses not otherwise included in research and development . for the years ended december 31 , 2020 and 2019 , selling , general and administrative expenses were $ 15.8 million and $ 6.3 million , respectively . 94 comparison of years ended december 31 , 2020 and 2019 ( $ 000 's ) replace_table_token_2_th license revenue increased $ 0.3 million in 2020 from $ 0 for the year ended december 31 , 2019 to $ 0.3 million for the year ended december 31 , 2020. the increase is due to the signing of the south korea agreement , described in more detail in note 3 to the consolidated financial statements included in this annual report on form 10-k. research and development expenses increased $ 70.1 million in 2020 from $ 2.6 million for the year ended december 31 , 2019 to $ 72.7 million for the year ended december 31 , 2020. the increase is primarily due to increased clinical trial and clinical material manufacturing costs related to the covid-19 clinical trials . story_separator_special_tag of these , we issued 316,666 shares to cheval . dr. dale chappell , who was serving as our ex-officio chief scientific officer at the time and currently serves as our chief scientific officer , controls bhc and reports beneficial ownership of all shares held by it and its affiliates , including cheval . after giving effect to the shares issued upon such conversions , no convertible notes issued in 2018 or 2019 were outstanding as of december 31 , 2020. as of december 31 , 2019 , we had accrued $ 0.1 million in interest related to the 2019 notes . interest expense related to the 2019 notes , recorded during the year ended december 31 , 2020 , was approximately $ 219,000 . 100 2019 bridge notes on june 28 , 2019 , we issued three short-term , secured bridge notes ( the “ june bridge notes ” ) evidencing an aggregate of $ 1.7 million of loans made to us by three parties : cheval , an affiliate of bhc , our controlling stockholder at the time , lent $ 750,000 ; nomis bay , our second largest stockholder at the time , lent $ 750,000 ; and dr. durrant , our chief executive officer and chairman of our board of directors , lent $ 200,000. the $ 1.7 million in proceeds was recorded as advance notes in the consolidated balance sheet as of december 31 , 2019. as previously disclosed , the june bridge notes were repaid in june 2020 with proceeds from the private placement , and the june bridge notes were extinguished . on november 12 , 2019 , we issued two short-term , secured bridge notes ( the “ november bridge notes ” and together with the june bridge notes , the “ 2019 bridge notes ” ) evidencing an aggregate of $ 350,000 of loans made us by two parties : cheval , an affiliate of bhc , our controlling stockholder at the time , lent $ 250,000 ; and cameron durrant , m.d . , mba , our chief executive officer and chairman of our board of directors , lent $ 100,000 . as previously disclosed , the november bridge notes were repaid in june 2020 with proceeds from the private placement . in april 2020 , we issued two short-term , secured bridge notes ( the “ april bridge notes ” and together with the june bridge notes and the november bridge notes , the “ bridge notes ” ) evidencing an aggregate of $ 350,000 of loans made to us : cheval , an affiliate of bhc , our controlling stockholder at the time , loaned $ 100,000 , and nomis bay , our second largest stockholder , loaned $ 250,000. the proceeds from the april bridge notes were used for working capital and general corporate purposes . as previously disclosed , these april bridge notes were repaid in june 2020 with proceeds from the private placement , and these bridge notes were extinguished . the bridge notes were secured by a lien on substantially all the company 's assets , which liens have been released . the bridge notes accrued interest at a rate of 7.0 % per annum . interest expense related to the bridge notes , recorded during the year ended december 31 , 2020 , was approximately $ 66,000 . 2020 convertible redeemable notes in march 2020 , we delivered two convertible redeemable promissory notes ( the “ 2020 notes ” ) evidencing loans with an aggregate principal amount of $ 518,333 made to us . the 2020 notes accrued interest at a rate of 7.0 % per annum and contained an original issue discount of $ 33,000 and $ 18,833 , respectively . we used the proceeds from the 2020 notes for working capital . as previously disclosed , the notes were repaid in june 2020 with proceeds from the private placement , and the notes were extinguished . interest expense related to the 2020 notes , recorded during the year ended december 31 , 2020 , was approximately $ 165,000. interest expense includes the original issue discount amortization of approximately $ 52,000 for the year ended december 31 , 2020. equity line of credit on november 8 , 2019 , we entered into a purchase agreement and a registration rights agreement with lincoln park , pursuant to which we had the right to sell to lincoln park up to $ 20,000,000 in shares of our common stock , subject to certain limitations and conditions set forth in the purchase agreement . in connection with the signing of the eloc purchase agreement on november 8 , 2019 , we issued 141,318 shares of its common stock to lpc . the issuance of the shares was recorded as debt issuance costs in common stock and additional paid-in capital with no net effect on stockholders ' equity ( deficit ) . during the months of december 2019 and january 2020 , we issued a total of 140,000 shares for aggregate proceeds of $ 0.3 million under the eloc purchase agreement . on june 2 , 2020 , following completion of the private placement , we notified lpc of our decision to terminate the eloc purchase agreement . the termination of the eloc purchase agreement became effective on june 3 , 2020 . 101 contracts eversana agreement on january 10 , 2021 , we announced that we had entered into a master services agreement ( the “ eversana agreement ” ) with eveersana life science services , llc ( “ eversana ” ) pursuant to which eversana will serve as our end-to-end commercial partner , providing us with a full suite of services in connection with the potential launch of lenzilumab . we will pay eversana fees and reimburse it for its expenses in performing the services as established in applicable statements of work . eversana has agreed to defer its fees pending our receipt of an

